G

Guardian Pharmacy Services Inc
NYSE:GRDN

Watchlist Manager
Guardian Pharmacy Services Inc
NYSE:GRDN
Watchlist
Price: 39.49 USD 1.15% Market Closed
Market Cap: $2.5B

Wall St Price Targets

GRDN Price Targets Summary
Guardian Pharmacy Services Inc

Wall Street analysts forecast GRDN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GRDN is 49.81 USD with a low forecast of 47.47 USD and a high forecast of 52.5 USD.

Lowest Forecast
Price Target
47.47 USD
20% Upside
Average Forecast
Price Target
49.81 USD
26% Upside
Highest Forecast
Price Target
52.5 USD
33% Upside
Guardian Pharmacy Services Inc Competitors:
Price Targets

Revenue
Forecast

15% / Year
Past Growth
6% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
15% / Year
Past Growth
6% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 5 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 6%.

Gross Profit
Forecast

15% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
15% / Year
Past Growth
9% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 5 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 9%.

Operating Income
Forecast

17% / Year
Past Growth
19% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
17% / Year
Past Growth
19% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 5 years, the compound annual growth rate for Operating Income has been 17%. The projected CAGR for the next 3 years is 19%.

Pre-Tax Income
Forecast

20% / Year
Past Growth
20% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
20% / Year
Past Growth
20% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 5 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 20%.

Net Income
Forecast

20% / Year
Past Growth
27% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
20% / Year
Past Growth
27% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

Over the last 5 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 27%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GRDN's stock price target?
Price Target
49.81 USD

According to Wall Street analysts, the average 1-year price target for GRDN is 49.81 USD with a low forecast of 47.47 USD and a high forecast of 52.5 USD.

What is the Revenue forecast for Guardian Pharmacy Services Inc?
Projected CAGR
6%

Over the last 5 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 3 years is 6%.

What is the Gross Profit forecast for Guardian Pharmacy Services Inc?
Projected CAGR
9%

Over the last 5 years, the compound annual growth rate for Gross Profit has been 15%. The projected CAGR for the next 3 years is 9%.

What is the Operating Income forecast for Guardian Pharmacy Services Inc?
Projected CAGR
19%

Over the last 5 years, the compound annual growth rate for Operating Income has been 17%. The projected CAGR for the next 3 years is 19%.

What is the Pre-Tax Income forecast for Guardian Pharmacy Services Inc?
Projected CAGR
20%

Over the last 5 years, the compound annual growth rate for Pre-Tax Income has been 20%. The projected CAGR for the next 3 years is 20%.

What is the Net Income forecast for Guardian Pharmacy Services Inc?
Projected CAGR
27%

Over the last 5 years, the compound annual growth rate for Net Income has been 20%. The projected CAGR for the next 3 years is 27%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett